PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas and Third Closing of a $20 Million Series B Financing

07.31.2017

BridgeBio Pharma Launches Eidos Therapeutics to Develop Targeted Therapy for Fatal Heart Disease

04.27.2017

Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

02.09.2017

BridgeBio Pharma Launches with a Focus on Precision Medicines for Genetic Diseases

01.03.2017

PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome

12.08.2016

page of 5

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn to keep up with all the latest news.

Links to an external site